VitaeBiomedical Co., Ltd.

Vitae Biomedical is a Taiwan-based company focused on developing non-invasive diagnostic solutions for early cancer detection. Our core technology is a urine-based test capable of detecting both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), providing a simple and patient-friendly alternative to conventional screening approaches.

Our solution is designed to complement existing screening methods such as low-dose CT (LDCT), particularly in addressing capacity limitations and improving accessibility for broader populations. The test has already been introduced in clinical service in Taiwan, demonstrating strong performance in real-world settings.

We are currently expanding our international collaborations and are particularly interested in working with hospitals and research institutions on clinical validation, pilot screening programs, and local data generation. Our approach allows flexible implementation, including bridging studies and early-stage deployment within existing healthcare workflows.

In parallel, we are developing a point-of-care testing (POCT) platform to enable rapid, on-site cancer screening, further supporting decentralized and scalable healthcare models.

We look forward to exploring potential collaborations in clinical research, early detection programs, and healthcare system integration.